Mechanisms in cardiac fibroblast growth: An obligate role for Skp2 and FOXO3a in ERK1/2 MAPK-dependent regulation of p27kip1

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 306, Issue 6, 2014, Pages

  Pramod, S ^a   Shivakumar, K ^a  

^a SREE CHITRA TIRUNAL INSTITUTE FOR MEDICAL SCIENCES AND TECHNOLOGY   (India)

Author keywords

Cardiac fibroblasts; ERK1 2; FOXO3a; p27; Skp2

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1B; MITOGEN ACTIVATED PROTEIN KINASE; S PHASE KINASE ASSOCIATED PROTEIN 2; TRANSCRIPTION FACTOR FKHRL1; FORKHEAD TRANSCRIPTION FACTOR; FOXO3A PROTEIN, RAT; MITOGENIC AGENT; S PHASE KINASE ASSOCIATED PROTEIN;

ANIMAL CELL; ANIMAL CELL CULTURE; ARTICLE; CARDIAC FIBROBLAST; CELL CYCLE PHASE; CELL GROWTH; CELL VIABILITY ASSAY; DNA SYNTHESIS; ENZYME ACTIVATION; FIBROBLAST; GENE OVEREXPRESSION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROCESSING; RAT; RNA INTERFERENCE; ANIMAL; ANIMAL MODEL; CARDIAC FIBROBLASTS; CELL CULTURE; CELL CYCLE; CELL PROLIFERATION; CYTOLOGY; DOWN REGULATION; DRUG EFFECT; ERK1/2; FOXO3A; HEART MUSCLE CELL; P27; PHOSPHORYLATION; PHYSIOLOGY; SIGNAL TRANSDUCTION; SKP2; SPRAGUE DAWLEY RAT;

CARDIAC FIBROBLASTS; ERK1/2; FOXO3A; P27; SKP2;

ANIMALS; CELL CYCLE; CELL PROLIFERATION; CELLS, CULTURED; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DOWN-REGULATION; FIBROBLASTS; FORKHEAD TRANSCRIPTION FACTORS; MALE; MAP KINASE SIGNALING SYSTEM; MITOGENS; MODELS, ANIMAL; MYOCYTES, CARDIAC; PHOSPHORYLATION; RATS; RATS, SPRAGUE-DAWLEY; S-PHASE KINASE-ASSOCIATED PROTEINS;

EID: 84900534332     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00933.2013     Document Type: Article

References (51)

1. Asada S, Daitoku H, Matsuzaki H, Saito T, Sudo T, Mukai H, Iwashita S, Kako K, Kishi T, Kasuya Y, Fukamizu A. Mitogenactivated protein kinases, Erk and p38, phosphorylate and regulate Foxo1. Cell Signal 19: 519-527, 2007.
2. Bashir T, Pagan JK, Busino L, Pagano M. Phosphorylation of Ser72 is dispensable for Skp2 assembly into an active SCF ubiquitin ligase and its subcellular localization. Cell Cycle 9: 971-974, 2010.
3. Besson A, Dowdy SF, Roberts JM. CDK inhibitors: cell cycle regulators and beyond. Dev Cell 14: 159-169, 2008.
4. Bhatt KV, Spofford LS, Aram G, McMullen M, Pumiglia K, Aplin AE. Adhesion control of cyclin D1 and p27Kip1 levels is deregulated in melanoma cells through BRAF-MEK-ERK signaling. Oncogene 24: 3459-3471, 2005.
5. Brown RD, Ambler SK, Mitchell MD, Long CS. The cardiac fibroblast: therapeutic target in myocardial remodeling and failure. Annu Rev Pharmacol Toxicol 45: 657-687, 2005.
6. Cen B, Mahajan S, Zemskova M, Beharry Z, Lin YW, Cramer SD, Lilly MB, Kraft AS. Regulation of Skp2 levels by the Pim-1 protein kinase. J Biol Chem 285: 29128-29137, 2010.
7. Chen Q, Xie W, Kuhn DJ, Voorhees PM, Lopez-Girona A, Mendy D, Corral LG, Krenitsky VP, Xu W, Moutouh-de Parseval L, Webb DR, Mercurio F, Nakayama KI, Nakayama K, Orlowski RZ. Targeting the p27 E3 ligase SCF(Skp2) results in p27-and Skp2-mediated cell-cycle arrest and activation of autophagy. Blood 111: 4690-4699, 2008.
8. Chen TP, Chen CM, Chang HW, Wang JS, Chang WC, Hsu SI, Cho CL. Increased expression of SKP2 and phospho-MAPK/ERK1/2 and decreased expression of p27 during tumor progression of cervical neoplasms. Gynecol Oncol 104: 516-523, 2007.
9. Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling-concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol 35: 569-582, 2000.
10. Delmas C, Manenti S, Boudjelal A, Peyssonnaux C, Eychène A, Darbon JM. The p42/p44 mitogen-activated protein kinase activation triggers p27Kip1 degradation independently of CDK2/cyclin E in NIH 3T3 cells. J Biol Chem 276: 34958-34965, 2001.
11. Dijkers PF, Medema RH, Pals C, Banerji L, Thomas NS, Lam EW, Burgering BM, Raaijmakers JA, Lammers JW, Koenderman L, Coffer PJ. Forkhead transcription factor FKHR-L1 modulates cytokinedependent transcriptional regulation of p27(KIP1). Mol Cell Biol 20: 9138-9148, 2000.
12. Dobson M, Ramakrishnan G, Ma S, Kaplun L, Balan V, Fridman R, Tzivion G. Bimodal regulation of FoxO3 by AKT and 14-3-3. Biochim Biophys Acta 1813: 1453-1464, 2011.
13. Du J, Guan T, Zhang H, Xia Y, Liu F, Zhang Y. Inhibitory crosstalk between ERK and AMPK in the growth and proliferation of cardiac fibroblasts. Biochem Biophys Res Commun 368: 402-407, 2008.
14. Foster JS, Fernando RI, Ishida N, Nakayama KI, Wimalasena J. Estrogens downregulate p27Kip1 in breast cancer cells through Skp2 and through nuclear export mediated by the ERK pathway. J Biol Chem 278: 41355-41366, 2003.
15. Frescas D, Pagano M. Deregulated proteolysis by the F-box proteins SKP2 and beta-TrCP: tipping the scales of cancer. Nat Rev Cancer 8: 438-449, 2008.
16. Gao D, Inuzuka H, Tseng A, Wei W. Akt finds its new path to regulate cell cycle through modulating Skp2 activity and its destruction by APC/ Cdh1. Cell Div 4: 11, 2009.
17. Henley SA, Dick FA. The retinoblastoma family of proteins and their regulatory functions in the mammalian cell division cycle. Cell Div 7: 10, 2012.
18. Hu Y, Wang X, Zeng L, Cai DY, Sabapathy K, Goff SP, Firpo EJ, Li B. ERK phosphorylates p66shcA on Ser36 and subsequently regulates p27kip1 expression via the Akt-FOXO3a pathway: implication of p27kip1 in cell response to oxidative stress. Mol Biol Cell 16: 3705-3718, 2005.
19. Huang H, Regan KM, Wang F, Wang D, Smith DI, van Deursen JM, Tindall DJ. Skp2 inhibits FOXO1 in tumor suppression through ubiquitin-mediated degradation. Proc Natl Acad Sci USA 102: 1649-1654, 2005.
20. Jones SM, Kazlauskas A. Growth-factor-dependent mitogenesis requires two distinct phases of signalling. Nat Cell Biol 3: 165-172, 2001.
21. Khattar E, Kumar V. Mitogenic regulation of p27(Kip1) gene is mediated by AP-1 transcription factors. J Biol Chem 285: 4554-4561, 2010.
22. Kortylewski M, Heinrich PC, Kauffmann ME, Böhm M, MacKiewicz A, Behrmann I. Mitogen-activated protein kinases control p27/Kip1 expression and growth of human melanoma cells. Biochem J 357: 297-303, 2001.
23. Krenning G, Zeisberg EM, Kalluri R. The origin of fibroblasts and mechanism of cardiac fibrosis. J Cell Physiol 225: 631-637, 2010.
24. Kress TR, Raabe T, Feller SM. High Erk activity suppresses expression of the cell cycle inhibitor p27Kip1 in colorectal cancer cells. Cell Commun Signal 8: 1, 2010.
25. Kumaran C, Shivakumar K. Calcium-and superoxide anion-mediated mitogenic action of substance P on cardiac fibroblasts. Am J Physiol Heart Circ Physiol 282: H1855-H1862, 2002.
26. Lees SJ, Childs TE, Booth FW. Age-dependent FOXO regulation of p27Kip1 expression via a conserved binding motif in rat muscle precursor cells. Am J Physiol Cell Physiol 295: C1238-C1246, 2008.
27. Lin HK, Wang G, Chen Z, Teruya-Feldstein J, Liu Y, Chan CH, Yang WL, Erdjument-Bromage H, Nakayama KI, Nimer S, Tempst P, Pandolfi PP. Phosphorylation-dependent regulation of cytosolic localization and oncogenic function of Skp2 by Akt/PKB. Nat Cell Biol 11: 420-432, 2009.
28. Lu M, Ma J, Xue W, Cheng C, Wang Y, Zhao Y, Ke Q, Liu H, Liu Y, Li P, Cui X, He S, Shen A. The expression and prognosis of FOXO3a and Skp2 in human hepatocellular carcinoma. Pathol Oncol Res 15: 679-687, 2009.
29. Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer 9: 153-166, 2009.
30. Mayorga M, Bahi N, Ballester M, Comella JX, Sanchis D. Bcl-2 is a key factor for cardiac fibroblast resistance to programmed cell death. J Biol Chem 279: 34882-34889, 2004.
31. Meloche S, Pouysségur J. The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1-to S-phase transition. Oncogene 26: 3227-3239, 2007.
32. Miragoli M, Gaudesius G, Rohr S. Electrotonic modulation of cardiac impulse conduction by myofibroblasts. Circ Res 98: 801-810, 2006.
33. Mirza AM, Gysin S, Malek N, Nakayama K, Roberts JM, McMahon M. Cooperative regulation of the cell division cycle by the protein kinases RAF and AKT. Mol Cell Biol 24: 10868-10881, 2004.
34. Orlowski RZ, Small GW, Shi YY. Evidence that inhibition of p44/42 mitogen-activated protein kinase signaling is a factor in proteasome inhibitor-mediated apoptosis. J Biol Chem 277: 27864-27871, 2002.
35. Palaniyandi SS, Sun L, Ferreira JCB, Mochly-Rosen D. Protein kinase C in heart failure: a therapeutic target? Cardiovasc Res 82: 229-239, 2009.
36. Philip L, Shivakumar K. cIAP-2 protects cardiac fibroblasts from oxidative damage: an obligate regulatory role for ERK1/2 MAPK and NF-κB. J Mol Cell Cardiol 62: 217-226, 2013.
37. Pillai MS, Sapna S, Shivakumar K. p38 MAPK regulates G1-S transition in hypoxic cardiac fibroblasts. Int J Biochem Cell Biol 43: 919-927, 2011.
38. Plas DR, Thompson CB. Akt activation promotes degradation of tuberin and FOXO3a via the proteasome. J Biol Chem 278: 12361-12366, 2003.
39. Porter KE, Turner NA. Cardiac fibroblasts: at the heart of myocardial remodeling. Pharmacol Ther 123: 255-278, 2009.
40. Ronnebaum SM, Patterson C. The FoxO family in cardiac function and dysfunction. Annu Rev Physiol 72: 81-94, 2010.
41. Sangeetha M, Pillai MS, Philip L, Lakatta EG, Shivakumar K. NF-κB inhibition compromises cardiac fibroblast viability under hypoxia. Exp Cell Res 317: 899-909, 2011
42. Santo EE, Stroeken P, Sluis PV, Koster J, Versteeg R, Westerhout EM. FOXO3a is a major target of inactivation by PI3K/AKT signaling in aggressive neuroblastoma. Cancer Res 73: 2189-2198, 2013.
43. Souders CA, Bowers SL, Baudino TA. Cardiac fibroblast the renaissance cell. Circ Res 105: 1164-1176, 2009.
44. Tzivion G, Dobson M, Ramakrishnan G. FoxO transcription factors; regulation by AKT and 14-3-3 proteins. Biochim Biophys Acta 1813: 1938-1945, 2011.
45. Villanueva J, Yung Y, Walker JL, Assoian RK. ERK activity and g1 phase progression: identifying dispensable versus essential activities and primary versus secondary targets. Mol Biol Cell 18: 1457-1463, 2007.
46. Weber KT, Sun Y, Bhattacharya SK, Ahokas RA, Gerling IC. Myofibroblast-mediated mechanisms of pathological remodelling of the heart. Nat Rev Cardiol 10: 15-26, 2013.
47. Weidinger C, Krause K, Klagge A, Karger S, Fuhrer D. Forkhead box-O transcription factor: critical conductors of cancer's fate. Endocr Relat Cancer 15: 917-929, 2008.
48. Yamamoto T, Ebisuya M, Ashida F, Okamoto K, Yonehara S, Nishida E. Continuous ERK activation downregulates antiproliferative genes throughout G1 phase to allow cell-cycle progression. Curr Biol 16: 1171-1182, 2006.
49. Yang JY, Hung MC. A new fork for clinical application: targeting forkhead transcription factors in cancer. Clin Cancer Res 15: 752-757, 2009.
50. Yang JY, Zong CS, Xia W, Yamaguchi H, Ding Q, Xie X, Lang JY, Lai CC, Chang CJ, Huang WC, Huang H, Kuo HP, Lee DF, Li LY, Lien HC, Cheng X, Chang KJ, Hsiao CD, Tsai FJ, Tsai CH, Sahin AA, Muller WJ, Mills GB, Yu D, Hortobagyi GN, Hung MC. ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation. Nat Cell Biol 10: 138-148, 2008.
51. Zhang S, Huan W, Wei H, Shi J, Fan J, Zhao J, Shen A, Teng H. FOXO3a/p27kip1 expression and essential role after acute spinal cord injury in adult rat. J Cell Biochem 114: 354-365, 2013.